Back to results
US 9,789,071 B2Granted
Intranasal formulation of epinephrine for the treatment of anaphylaxis
AssigneeG2B Pharma, Inc.
InventorNigel Ten Fleming
Life of this patent
Estimating the term…
Abstract
This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
Claims14
A pharmaceutical composition comprising:
- an anti-anaphylactic agent, wherein the anti-anaphylactic agent is epinephrine, and
- a vasodilator, wherein the vasodilator is phentolamine,
- wherein the composition is a dry powder intranasal spray that provides a dose of at least 0.01 mg of epinephrine and about 0.01 mg to about 0.1 mg of phentolamine per kg body weight of a patient.
Dependencies are inferred from the claim text.